Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CMV pp65 dendritic cell vaccine
- Development stage
- Unknown
- Lead developer
- Immunomic Therapeutics
- Modality
- Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies, Vaccines & Immunotherapeutics
- Administration
- Intradermal, Subcutaneous
01
Overview
The CMV pp65 dendritic cell vaccine is an investigational immunotherapy designed to stimulate the immune system against cytomegalovirus (CMV) antigens present in certain tumors. The therapy involves isolating a patient’s own (autologous) dendritic cells and loading them with the mRNA or peptides encoding the immunodominant CMV protein pp65. These antigen-loaded cells are then administered back to the patient to induce a targeted cytotoxic T-cell response against tumor cells expressing the viral antigen. This approach has been primarily studied in glioblastoma multiforme (GBM), where evidence suggests that vaccination can enhance anti-tumor immunity and may improve survival outcomes[5][6][7].
- Other names
- cytomegalovirus pp65 peptide-pulsed autologous dendritic cell vaccineCMV RNA-pulsed dendritic cells vaccine
Beyond the preview
Go deeper on CMV pp65 dendritic cell vaccine.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CMV pp65 dendritic cell vaccine.